Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 9
Submit an article Journal homepage
100
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study*

Barry J. Goldstein Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
,
Peter N. Weissman University of Miami School of Medicine, Miami, FL, USA
,
Margaret J. Wooddell GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USACorrespondence[email protected]
,
Brian R. Waterhouse GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
&
Alexander R. Cobitz GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
Pages 1715-1723 | Accepted 12 Jun 2006, Published online: 27 Jul 2006

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Gabriela Berg & Veronica Miksztowicz. (2015) Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes. Metalloproteinases in Medicine 2, pages 51-59.
Read now
Anthony H Barnett. (2009) Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vascular Health and Risk Management 5, pages 141-151.
Read now
Amit Agrawal. (2009) Effectiveness of the Early Addition of Rosiglitazone to Control Hyperglycemia after Unsuccessful Submaximal Sulphonylurea Monotherapy: The Rosiglitazone Early versus SULphonylurea Titration (RESULT) Study. The Physician and Sportsmedicine 37:1, pages 146-148.
Read now
Kosmas I. Paraskevas & Dimitri P. Mikhailidis. (2008) C-reactive protein (CRP): more than just an innocent bystander?. Current Medical Research and Opinion 24:1, pages 75-78.
Read now

Articles from other publishers (12)

Xianda Chen, Shuaixing Wang, Wenli Xu, Mingming Zhao, Youyi Zhang & Han Xiao. (2023) Metformin Directly Binds to MMP-9 to Improve Plaque Stability. Journal of Cardiovascular Development and Disease 10:2, pages 54.
Crossref
Elaheh Foroumandi, Sorayya Kheirouri, Rahmat Nosrati & Ramin Ghodsi. (2021) Association of dietary intake, medication and anthropometric indices with serum levels of advanced glycation end products, caspase-3, and matrix metalloproteinase-9 in diabetic patients. Journal of Diabetes & Metabolic Disorders 20:1, pages 719-725.
Crossref
J. Seufert & B. Gallwitz. (2014) The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes, Obesity and Metabolism 16:8, pages 673-688.
Crossref
Stefano Genovese, Giorgia De Berardis, Antonio Nicolucci, Edoardo Mannucci, Virgilio Evangelista, Licia Totani, Fabio Pellegrini & Antonio Ceriello. (2013) Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes. Advances in Therapy 30:2, pages 190-202.
Crossref
Chiara Busti, Emanuela Falcinelli, Stefania Momi & Paolo Gresele. (2009) Matrix metalloproteinases and peripheral arterial disease. Internal and Emergency Medicine 5:1, pages 13-25.
Crossref
Marjolijn CE Bragt, Jogchum Plat, Marco Mensink, Patrick Schrauwen & Ronald P Mensink. (2009) Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus. BMC Endocrine Disorders 9:1.
Crossref
Jochen Seufert. (2009) The backbone of oral glucose-lowering therapy: time for a paradigm shift?. Fundamental & Clinical Pharmacology 23:6, pages 651-667.
Crossref
Sinem Kiyici, Canan Ersoy, Aysel Kaderli, Murat Fazlioglu, Ferah Budak, Cevdet Duran, Ozen Oz Gul, Deniz Sigirli, Ibrahim Baran, Ercan Tuncel, Erdinc Erturk & Sazi Imamoglu. (2009) Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Research and Clinical Practice 86:1, pages 44-50.
Crossref
M. Fisher. (2009) Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International Journal of Clinical Practice 63:9, pages 1354-1368.
Crossref
P. D. Home & G. Pacini. (2008) Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes, Obesity and Metabolism 10:9, pages 699-718.
Crossref
M.C.E. Bragt & H.E. Popeijus. (2008) Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiology & Behavior 94:2, pages 187-197.
Crossref
A. Macías Batista, I. Peiró Martínez & P.L. de Pablos Velasco. (2008) Terapia combinada. Endocrinología y Nutrición 55, pages 58-65.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.